Vitiligo ve D Vitamini
Özet
Vitiligo, deri ve mukozaları tutan, keskin sınırlı depigmente yamalarla karakterize, kişinin yaşam kalitesini bozan otoimmün bir deri hastalığıdır. Etyopatogenezinde genetik, nöral, otoimmünite ve oksidatif stres gibi çoklu faktörler rol oynamaktadır. En çok deride eksprese olan D vitamini reseptörleri (VDR), melanositler ve immün sistem hücreleri üzerinde önemli etkilere sahiptir. D vitamini, Th2 hücrelerini uyararak antiinflamatuvar sitokinleri artırırken, Th1, Th9 ve Th17 hücrelerini inhibe edip proinflamatuvar sitokinleri azaltarak immünregülatör bir rol üstlenir. Ayrıca serbest oksijen radikallerini azaltarak antioksidan ve fotokoruyucu etki gösterir, melanositleri hasardan korur ve melanin sentezini uyarır. Vitiligolu hastalarda, özellikle eşlik eden başka bir otoimmün hastalık varlığında, D vitamini düzeyleri genellikle düşük veya yetersiz bulunmuştur. Tedavide topikal D vitamini analogları (kalsipotriol, takalsitol) tek başlarına sınırlı etki gösterse de, topikal kortikosteroidler, dar bant UVB ve PUVA gibi fototerapilerle kombine edildiklerinde repigmentasyon başarısını anlamlı ölçüde artırmakta ve fototerapinin yan etkilerini azaltmaktadır. Sistemik yüksek doz D vitamini takviyesinin de kalsiyum kısıtlaması ve uygun hidrasyonla erişkinlerde repigmentasyon sağladığı ve hastalık aktivitesini azalttığı bildirilmiştir. Sonuç olarak D vitamini, immünomodülatör ve melanojenik etkileriyle vitiligo tedavisinde değerli bir seçenektir.
Vitiligo is an autoimmune skin disease characterized by sharply demarcated depigmented patches affecting the skin and mucous membranes, which impairs the patient's quality of life. Multiple factors, including genetics, neural mechanisms, autoimmunity, and oxidative stress, play a role in its etiopathogenesis. Vitamin D receptors (VDR), which are mostly expressed in the skin, have significant effects on melanocytes and immune system cells. Vitamin D exerts an immunoregulatory role by stimulating Th2 cells to increase anti-inflammatory cytokines, while inhibiting Th1, Th9, and Th17 cells to decrease proinflammatory cytokines. Furthermore, it exhibits antioxidant and photoprotective effects by reducing reactive oxygen species, thereby protecting melanocytes from damage and stimulating melanin synthesis. Vitamin D levels are generally found to be low or deficient in patients with vitiligo, particularly in the presence of comorbid autoimmune diseases. In terms of treatment, while topical vitamin D analogs (calcipotriol, tacalcitol) show limited efficacy as monotherapy, their combination with topical corticosteroids or phototherapies such as narrowband UVB and PUVA significantly enhances repigmentation success and reduces the side effects of phototherapy. Systemic high-dose vitamin D supplementation, accompanied by a low-calcium diet and adequate hydration, has also been reported to achieve repigmentation and decrease disease activity in adults. Consequently, vitamin D serves as a valuable option in vitiligo management due to its immunomodulatory and melanogenic properties.
Referanslar
1.Bergqvist C,Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571-92.
Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473-91
Driessche FV, Silverberg N. Pediatr current management of pediatric vitiligo. Drugs. 2015; 17:303–13.
Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-12.
5 Arıcan O, Koç K, Ersoy L. Clinical characteristics in 113 Turkish vitiligo patients. Acta Dermatovenerol Alp Pannonica Adriat. 2008;17:129-32.
6.Akbaş A, Kılınç F, Yakut Hİ, et al. Dermatologic diseases presenting with pigmentation disorders in children: a single center experience. Journal of Pediatric Sciences. 2015;7:1-8.
Ezzedine K, Lim HW, Suzuki T, et al. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and relatedissues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25(3):E1–13.
8.Sehgal VN, Srivastava G.Vitiligo: compendium of clinico-epidemiological features. India J Dermatol Venereol Leprol. 2007;73(3): 149–56.
9.Said-Fernandez SL,Sanchez-Domínguez CN, Salinas-Santander MA, et al.Novel immunological and genetic factors associated with vitiligo:a review J.Exp Ther Med. 2021;21(4):312.
Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: a meta-analysis. PLoS One. 2016; 11(9):e0163806
Ezzedine K, Silverberg N. A Practical approach to the diagnosis and treatment of vitiligo in children. Pediatrics. 2016;138. pii: e20154126
12.Rodrigues M, Ezzedine K, Hamzavi I, et al. Vitiligo Working Group. New discoveries in the pathogenesis and classificatio of vitiligo. J Am Acad Dermatol. 2017; 77(1): 1–13.
13.Van Geel N, Mollet I, Brochez L, et al. New in sights in segmental vitiligo: case report and review of theories. Br J Dermatol. 2012; 166(2): 240–6.
Attili SK. Segmental and generalized vitiligo: both forms demonstrate inflammatory histopathological features and clinicalmosaicism. Indian J Dermatol. 2013;58(6): 433–8.
15.Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet. 1994; 55(5): 981–90.
Spritz RA, Andersen GH. Genetics of vitiligo. Dermatol Clin. 2017;35(2):245–55.
17.Kemp EH, Gawkrodger DJ, Watson PF, et al. Immuno precipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol. 1997 ;109(3):495–500.
Gökçek GE, Öksüm Solak E,et al. Vitiligo tanılı hastalarda interferon-gamma/ interlökin-10 oranının hastalık aktivitesi ve yaygınlığı ile ilişkisi. Bozok Tıp Derg. 2020;10(1):217-26
19.Ürün M, Görgülü A, Pişkin S, et al. Vitiligolu hastaların psikiyatrik durumları. Dermatoz 2013; 4(1): 7-11.
Kutlubay Z, Uzunçakmak TK, Engin B, et al. Vitiligo and oxidative stress. J Türk Acad Dermatol. 2011;5(4)1154r1
Speeckaert R, Dugardin J, Lambert J, et al. Critical appraisal of the oxidative stress pathway invitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018 ;32(7): 1089–98.
22.Akoglu G, Emre S, Metin A, et al. Evaluation of total oxidant and antioxidant status in localized and generalized vitiligo. Clin Exp Dermatol. 2013;38(7):701-6.
23.Kuhtreiber WM, Hayashi T, Dale EA, et al. Central role of defective apoptosis in autoimmunity. J Mol Endocrinol. 2003;31(3):373-99.
Sandoval-Cruz M, Garcia-Carrasco M, Sanchez- Porras R,et al. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011;10(12): 762–5.
Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003; 16(2):90–100.
26.Norris DA, Kissinger RM, Naughton GM, et al. Evidence for immunologicmechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol. 1988; 90(6): 783–9.
Benzekri L, Gauthier Y. Clinical markers of vitiligo activity. J Am Acad Dermatol. 2017;76(5): 856–62.
28 .Harris JE, Cellular stress and innate inflammation in organ-specific autoimmunity: Lessons learned from vitiligo. Immunol Rev.2016; 269:11–25.
Dwivedi M, Kemp EH, Laddha NC, et al. Regulatory T cells in vitiligo: ımplications for pathogenesis and therapeutics. Autoimmun Rev. 2015;14(1):49-56.
Laddha NC, Dwivedi M, Mansuri MS, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol. 2014;23:352–3.
31.Köse O , Özmen İ. Çocukluk çağı vitiligosu. Turkderm. 2011; 45( Suppl 2): 117-21.
Ezzedine K, Eleftheriadou V, Whitton M, et al.Vitiligo. Lancet. 2015; 386(9988):74–84.
33.Kumar Jha A, Sonthalia S, Lallas A, et al. Dermoscopy in vitiligo: diagnosis and beyond. Int J Dermatol. 2018 ; 57(1):50–4.
Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg. 2012;16(4):261-6.
Gill L, Zarbo A, Isedeh P,et al.Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol. 2016;74(2):295-302.
36.Percivalle S, Piccinno R, Caccialanza M. Concurrence of vitiligo and psoriasis: a simple coincidence? Clin Exp Dermatol. 2009;34(1):90-1.
37.Rodrigues M, Ezzedine K, Hamzavi I, et al. Vitiligo Working Group. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017 ;77(1):17–29.
Baykal L, Bahadır S. Çocuklarda vitiligo tedavsi ve yeni tedavi yaklaşımları. 2015; Dermatoz /2/dermatoz doi:10.15624 Dermatoz 15062d2.
39.Taieb A, Alomar A, Böhm M,et al. Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europe´enne desMe´decinsSpe´cialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168:5-19.
40.Gianfaldoni S, Wollina U, Tchernev G, et al.Vitiligo in children: a review of conventional treatments. Open Access Maced J Med Sci. 2018;6:213-7.
Akbas A, Kılınç F, Aktas A. Clınical and demographic characteristics of children with vitiligo: retrospective analysis of 105 cases. Turkish J. Pediatr Dis. 2019; Doi: 10.12956/Tchd.538826
42.Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin d: an endocrine society scientific statement. Endocrine Reviews.2 012; 33(3): 456492.
43.Heriniaina RM , Banerjee P, Jinpeng Lu J,et al. Revıew of the relatıonshıp between vıtamın d and vıtılıgo. International Journal Of Recent Scientific Research(IJSR). 2016; 7(8):12982-6.
44 .Charoenngam N , Holick MF .Immunologic effects of vitamin d on human health and disease. Nutrients. 2020;12(7): 2097.doi: 10.3390/nu12072097PMCID: PMC7400911PMID: 32679784
45.K. AlGhamdi, A. Kumar, N. Moussa. The role of vitaminD in melanogenesis with an emphasis on vitiligo. Indian J Dermatol Venereol, and Leprol. 2013; 79( 6):750–8.
46.M Kıdır. D vitamininin, immün sistem, deri ve kanser ile ilişkisi. S.D.Ü. Tıp Fak. Derg. 2013;20(4):158-61.
Bikle DD, Vitamin D and the skin, J. Bone. Miner. Metab. 2010 ; 28(2): 117-30.
48 . Birlea SA, Costin GE, Norri DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev. 2009;29:514–46.
49 . Silverberg JI, Silverberg AI, Malka E, et al. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010;62:937–41.
Mostafa WZ, Hegazy RA. Vitamin D and the skin: Focus on a complex relationship:a review. J Adv Res. 2015;6(6):793-804.
51.Penna G, Adorini L. 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000; 164: 2405–11.
Singh S, Singh U, Pandey S S.Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in vitiligo patients. Indian J Dermatol. 2012; 57 :12-4.
B. Sauer, L. Ruwisch,B. Kleuser, “Antiapoptotic action of1α,25-dihydroxyvitamin D3 in primary human melanocytes,” Melanoma Research.2003;13( 4): 339–47.
L. Tang, W. Fang, J. Lin, et al.“Vitamin D protects human melanocytes against oxidative damage by activation of Wnt/β-catenin signaling,” Laboratory Investigation 2018 ;98(12:,1527–37.
Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008;9:345-59.
56.H. Watabe, Y. Soma, Y. Kawa et al. Differentiation of murinemelanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol. 2002;119 (3). 583–9.
57.Ersoy-Evans S, Commentary: vitamin D and autoimmunity. Is there an association? J Am Acad Dermatol. 2010;62(6) 942–4.
58.Ustun I, Seraslan G, Gokce C, et al. Investigation of vitamin D levels in patients with vitiligo vulgaris. Acta Dermatovenerol Croat. 2014;22:110–3.
59.Varikasuvu SR, Aloori S, Varshney S,et al. Decreased circulatory levels of vitamin d in vitiligo: a meta-analysis. An Bras Dermatol. 2021;96(3):284-94.
Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta-analysis. Photodermatol Photoimmünol Photomed. 2016;32(4):181-90.
61.Y. Dong, N. Pollock, I. S. Stallmann-Jorgensen et al. Low 25-hydroxyvitamin D levels in adolescents: race, season, adiposity, physical activity, and fitness. Pediatrics.2010;125(6),1104–11.
62.Saleh HM, Abdel Fattah NS, Hamza HT. Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. Photodermatol Photoimmünol Photomed. 2013;29:34–40.
63.Beheshti A, Ghadami H, Barikani A, Haj Manouchehri F. Assessment of vitamin D plasma levels in patientswith vitiligo vulgaris. Acta Medica Iranica. 2014;52(8): 601–6.
Karagün E. Ergin C, Baysak, S, et al. The role of serum vitamin D levels in vitiligo. Postepy dermatology and alergologyi, 2016 ;33(4): 300–2.
65.Shalaby MES, Ibrahim SM, Shorbagy MSE, Ahmed RAE. Evaluationof serum level of 25-hydroxy vitamin D in vitiligo patients. Gulf J Dermatology Venereol. 2017;24:45-9.
66 Willis M, Laing EM , Hall DB,et al. A prospective analysis of plasma 25-hydroxyvitamin D concentrations in white and black prepubertal females in the southeastern United States. American Journal of Clinical Nutrition. 2017; 85(1):124–30.
67.Zhang X, Wang W, Li Y,et al. Serum 25-hydroxyvitamin D status in chinese children with vitiligo: a case-control study. Clin Pediatr (Phila). 2018 ;57(7):802-5.
68.Alshiyab DM , Al-qarqaz FA , Heis LH , et al. Assessment of serum vitamin d levels in patients with vitiligo in Jordan: a case-control study. Dermatol Res Prac. 2019;Article ID 2048409, 4pageshttps://doi.org/10.1155/2019/2048409
Amer AM, Khater EMG, Marei AM,et al. Evaluation of serum level of 25-hydroxy vitamin d in vitiligo patients. Zagazig Univ Med J. 2019;25:935-40.
70.Takci Z, Teki̇n Ö, Ertugrul DT, et al. A case-control study: evaluation of vitamin D metabolism in patients with vitiligo. Turk J Med Sci. 2015; 45(4): 837–41.
71.Lajevardi V. L, Nazemi MJ, Khodashenas Z, et al. Vitamin D serum level in vitiligo patients: a case-control study from Iran. Iranian Journal of Dermatology.2014; 17(2): 59-62.
Doss RW, El-Rifaie AA, Gohary YM, et al. Vitamin D receptor expression in vitiligo. Indian J Dermatol. 2015;60:544-8.
Xu X, Fu W.W, Wu W.Y. Serum 25-hydroxyvitamin D deficiency in Chinese patients with vitiligo: a case-control study. PLoS One. 2012;7:e52778.
74.Khurrum H, AlGhamdi KM. The relationship between the serum level of vitamin d and vitiligo: a controlled study on 300 subjects. J Cutan Med Surg. 2016;20(2):139-45.
75.Prakash D, Karthikeyan K. A case control study of vitamin D levels in patients with vitiligo. Int J Res Dermatol. 2017;3:103
76.Navarro-Triviño FJ, Arias-Santiago S, Gilaberte-Calzada Y. Vitamin D and the Skin: A Review for Dermatologists. Actas Dermosifiliogr (Engl Ed).2019;110(4):262-272.. doi: 10.1016/j.ad.2018.08.006. Epub 2019 Mar 8. PMID: 30857638
77.Sehrawat M, Arora TC, Chauhan A, et al. Correlation of vitamin d levels with pigmentation in vitiligo patients treated with nbuvb therapy. ISRN Dermatol. 2014 Mar 23;2014:493213. doi: 10.1155/2014/493213. PMID: 25006488; PMCID: PMC4005019.
Finamor DC, Sinigaglia-Coimbra R, Neves LCM, et al. M, A pilot study assessing the effect of prolonged administration of high daily doses of vitamin d on the clinical course of vitiligo and psoriasis. Dermato Endocrin. 2013;5(1):222-34.
Karaguzel G, Sakarya NP, Bahadir S, et al. Vitamin d status and the effects of oral vitamin d treatment in children with vitiligo: A prospective study. Clin Nutrition. 2016;15:28-31.
Lotti T, Buggiani G, Troiano M, et al. Targeted and eombination treatments for vitiligo. Comparative evaluation of different eurrent Dermatol Ther. 2008;21( Suppl l):20-6.
81.Arca E, Tastan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006;33(5):338-43.
Hartmann A, Lurz C, Hamm H, et al. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol. 2005;44:736- 42.
83.Ada S, Sahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmünol Photomed 2005;21:79-83.
Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol.2001;145:476-9.
Chiavérini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002;16:137-8.
86.Travis LB, Silverberg NB: Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol. 2004;21:495-8.
87.Gargoom AM, Duweb GA, Elzorghany AH, et al. Calcipotriol in the treatment of childhood vitiligo. Int J Clin Pharmacol Res .2004;24:11-4.
Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.J Eur Acad Dermatol Venereol. 2006;20:269-73.
Kose O, Gur AR, Kurumlu Z, Erol E. Calcipotriol ointment versus clobetasol ointment in localized vituigo: an open, comparative clinical trial. Int J Dermatol. 2002;41:616-8.
90.Wat H,Dytoc M. Off-label uses of topical vitamin d in dermatology: Canadian Dermatology Association. Journal of Cutaneous Medicine and Surgery. 2014; 18(2): 91-108.
Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology. 1998;197:167–70.
Sarma N, Singh AK. Topical calcipotriol in childhood vitiligo: an Indian experience. Int J Dermatol. 2004;43:856-9.
Katayama I, Ashida M, Macda A, et al. Open trial of topical tacaleitol [1 alpha 24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol. 2003;13:372-6.
Rodriguez-Martin M, Garcia Bustinduy M, Saez Rodriguez M, et al. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol. 2009; 160:409-14.
'Whitton ME, Pinart M, Batehelor J, et al. Interventions for vitiligo. Coehrane Database Syst Rev. 2010;(1:)CD003263.
Göktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006;20:553-7.
97.Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmünol Photomed. 2004;20(5):248-51. doi: 10.1111/j.1600-0781.2004.00114.x. PMID: 15379875.
Leone G, Pacifico A, IacoveUi P, et al. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol. 2006; 31:200-5, doi:10.11U/).1365-2230.2005.02037.x.
Cherif F, Azaiz MI, Ben Hamida A, et al. Calcipotriol and PUVA as treatment for vitiligo. Dermatol Online J. 2003;9(5):4.
Yalcin B, Sahin S, Bukulmez G, et al. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study. J Am Acad Dermatol. 2001;44:634-7.
Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol. 2001;145(3):472-5.
Baysal V, Yildirim M, Erel A, Kesici D. Is the combination of calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol. 2003;17:299-302.
103.Lu-yan T, Wen-wen F, Lei-hong X, et al. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmünol Photomed 2006;22:310-4.
104 . Goldinger SM, Dummer R, Schmid P, Burg G, Seifert B, Läuchli S. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 2007;21(4):504-8.
Dwiyana RF , Pramita K.C. Nugrahaini,et al. D.P. Dermatoloji Reports. The efficacy of vitamin D supplementation in increasing 25-hydroxyvitamin D levels in childhood vitiligo patients receiving 308-nm-excimer light phototherapy dermatoloji reports 2019; 11(s1)https://doi.org/10.4081/dr.2019.8049
